Diseases /
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: This entity includes cases that have clinical, laboratory, and morphologic features that support the diagnosis of both a myelodysplastic syndrome and a myeloproliferative neoplasm, but do not meet the criteria for any of the other entities included in the myelodysplastic/myeloproliferative neoplasm category. (WHO, 2001) [1]
Myelodysplastic/myeloproliferative neoplasm, unclassifiables most frequently harbor alterations in ASXL1, JAK2, U2AF1, TET2, and SRSF2 [2].
ASXL1fs, JAK2 V617F, JAK2 Mutation, JAK2 Exon 14 Mutation, and U2AF1 Mutation are the most common alterations in myelodysplastic/myeloproliferative neoplasm, unclassifiable [2].
Significant Genes in Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.